Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY22 results · Oct–Dec 2021
Torrent Pharmaceuticals reported revenue from operations of ₹2,108.00 crore (up 5.7% from Q3 FY21) and net profit of ₹249.00 crore (down 16.2% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,108.00 | 1,995.00 | +5.7% | 2,137.00 | −1.4% |
| Other income | 48.00 | 8.00 | +500.0% | 51.00 | −5.9% |
| Total income | 2,156.00 | 2,003.00 | +7.6% | 2,188.00 | −1.5% |
| Profit before tax | 357.00 | 357.00 | +0.0% | 472.00 | −24.4% |
| Net profit for the period | 249.00 | 297.00 | −16.2% | 316.00 | −21.2% |
| EPS, basic (₹) | 14.75 | 17.52 | −15.8% | 18.63 | −20.8% |
| Net margin (%) | 11.8 | 14.9 | 14.8 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,588.00 | 1,616.00 | −1.7% | 1,799.00 | −11.7% |
| Other income | 37.00 | 11.00 | +236.4% | 54.00 | −31.5% |
| Total income | 1,625.00 | 1,627.00 | −0.1% | 1,853.00 | −12.3% |
| Profit before tax | 255.00 | 339.00 | −24.8% | 454.00 | −43.8% |
| Net profit for the period | 170.00 | 278.00 | −38.8% | 326.00 | −47.9% |
| EPS, basic (₹) | 10.06 | 16.45 | −38.8% | 19.24 | −47.7% |
| Net margin (%) | 10.7 | 17.2 | 18.1 |
Consolidated
- Filed with BSE
- 25 Jan 2022, 19:19 IST
- Board meeting
- 25 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jan 2022, 19:19 IST
- Board meeting
- 25 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Audited
- Source
- XBRL filing on BSE